NasdaqGS:NVCRMedical Equipment
NovoCure (NVCR) Is Up 10.9% After Raising 2026 Revenue Outlook and Securing New CE Mark Approval – Has The Bull Case Changed?
NovoCure recently reported its strongest-ever second quarter, with net revenue rising to US$183.58 million, a smaller net loss of US$15.66 million, and an upgraded 2026 net revenue outlook to US$710 million–US$725 million.
The company also secured a CE Mark for its Optune Pax device in locally advanced pancreatic cancer and is anticipating FDA premarket approval for TTFields in brain metastases from non-small cell lung cancer, underscoring how expanding indications could reshape its...